27.03.2017 • News

A. Schulman Hikes European Masterbatch Capacity

(c) Srebrina Yaneva
(c) Srebrina Yaneva

US plastics compounder and distributor A. Schulman has announced it will increase production capacity for color masterbatches in Europe in order to meet growing market demand.

Three additional extruders will be added at its facilities in Hungary, Italy and Poland. Heinrich Lingnau, senior vice president and general manager, Europe, Middle East and Africa, said the expansion is the third recent significant investment in its masterbatch manufacturing sites.

The Fairlawn, Ohio-headquartered company has also added masterbatch capacity in Changshu, China, and Istanbul, Turkey. A new facility opened at the Changshu High Tech Industrial Park in China’s Jiangsu province in April 2016 in order to meet growing demand. This new plant, Schulman’s second wholly owned plant in the People’s Republic, produces premium color additives for packaging, automotive, agricultural, sports, leisure & home customers both in China and other growing markets in the Asia-Pacific region.

In Turkey, a new production line is due to start production in spring 2017. Located in the greater Istanbul area, the facility will produce approximately 18,000 t/y of premium additive, white and natural masterbatches for food and industrial packaging customers.

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read